

Highlights of This Issue 261


COMMENTARY

- 263** Mitogen-Activated Protein Kinases Inhibitors: Potential Therapeutic Agents for Cancer Cachexia
Vickie E. Baracos

REVIEW

- 265** Strategies to Overcome Bypass Mechanisms Mediating Clinical Resistance to EGFR Tyrosine Kinase Inhibition in Lung Cancer
Hatim Husain, Michael Scur, Ayesha Murtuza, Nam Bui, Brian Woodward, and Razelle Kurzrock

SMALL MOLECULE THERAPEUTICS

- 273** A Novel LSD1 Inhibitor T-3775440 Disrupts GF11B-Containing Complex Leading to Transdifferentiation and Impaired Growth of AML Cells
Yoshinori Ishikawa, Kanae Gamou, Masato Yabuki, Shinji Takagi, Kosei Toyoshima, Kazuhide Nakayama, Akiko Nakayama, Megumi Morimoto, Hitoshi Miyashita, Ryo Dairiki, Yukiko Hikichi, Naoki Tomita, Daisuke Tomita, Shinichi Imamura, Misa Iwatani, Yusuke Kamada, Satoru Matsumoto, Ryujiro Hara, Toshiyuki Nomura, Ken Tsuchida, and Kazuhide Nakamura
- 285** Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers
 Kaiming Sun, Ruzanna Atoyian, Mylissa A. Borek, Steven Dellarocca, Maria Elena S. Samson, Anna W. Ma, Guang-Xin Xu, Troy Patterson, David P. Tuck, Jaye L. Viner, Ali Fattaey, and Jing Wang
- 300** Niclosamide Inhibits Oxaliplatin Neurotoxicity while Improving Colorectal Cancer Therapeutic Response
Olivier Cerles, Evelyne Benoit, Christiane Chéreau, Sandrine Chouzenoux, Florence Morin, Marie-Anne Guillaumot, Romain Coriat, Niloufar Kaviani, Thomas Loussier, Pietro Santulli, Louis Marcellin, Nathaniel E.B. Saidu, Bernard Weill, Frédéric Batteux, and Carole Nicco

LARGE MOLECULE THERAPEUTICS

- 312** Blocking the CCL2-CCR2 Axis Using CCL2-Neutralizing Antibody Is an Effective Therapy for Hepatocellular Cancer in a Mouse Model
Kun-Yu Teng, Jianfeng Han, Xiaoli Zhang, Shu-Hao Hsu, Shun He, Nissar A. Wani, Juan M. Barajas, Linda A. Snyder, Wendy L. Frankel, Michael A. Caligiuri, Samson T. Jacob, Jianhua Yu, and Kalpana Ghoshal
- 323** Dual-Targeting Nanoparticles for *In Vivo* Delivery of Suicide Genes to Chemotherapy-Resistant Ovarian Cancer Cells
Emiliano Cocco, Yang Deng, Erik M. Shapiro, Ileana Bortolomai, Salvatore Lopez, Ken Lin, Stefania Bellone, Jiajia Cui, Gulden Menderes, Jonathan D. Black, Carlton L. Schwab, Elena Bonazzoli, Fan Yang, Federica Predolini, Luca Zammataro, Gary Altwerger, Christopher de Haydu, Mitchell Clark, Julio Alvarenga, Elena Ratner, Masoud Azodi, Dan-Arin Silasi, Peter E. Schwartz, Babak Litkouhi, W. Mark Saltzman, and Alessandro D. Santin

CANCER BIOLOGY AND SIGNAL TRANSDUCTION


- 334** Selumetinib Attenuates Skeletal Muscle Wasting in Murine Cachexia Model through ERK Inhibition and AKT Activation
 Yang Quan-Jun, Huo Yan, Han Yong-Long, Wan Li-Li, Li Jie, Huang Jin-Lu, Lu Jin, Chen Peng-Guo, Gan Run, and Guo Cheng
- 344** Dual Inhibition of MEK and PI3K/Akt Rescues Cancer Cachexia through both Tumor-Extrinsic and -Intrinsic Activities
Erin E. Talbert, Jennifer Yang, Thomas A. Mace, Matthew R. Farren, Alton B. Farris, Gregory S. Young, Omar Elnaggar, Zheng Che, Cynthia D. Timmers, Priyani Rajasekera, Jennifer M. Maskarinec, Mark Bloomston, Tanios Bekaii-Saab, Denis C. Guttridge, and Gregory B. Lesinski
See related article, p. 357
- 357** Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer
Yoshihisa Kobayashi, Koichi Azuma, Hiroki Nagai, Young Hak Kim, Yosuke Togashi, Yuichi Sesumi, Masato Chiba, Masaki Shimoji, Katsuaki Sato, Kenji Tomizawa, Toshiki Takemoto, Kazuto Nishio, and Tetsuya Mitsudomi
See related article, p. 344

Table of Contents

- 365** **Imatinib Spares cKit-Expressing Prostate Neuroendocrine Tumors, whereas Kills Seminal Vesicle Epithelial–Stromal Tumors by Targeting PDGFR- β**
Elena Jachetti, Alice Rigoni, Lucia Bongiovanni, Ivano Arioli, Laura Botti, Mariella Parenza, Valeria Cancila, Claudia Chiodoni, Fabrizio Festinese, Matteo Bellone, Regina Tardanico, Claudio Tripodo, and Mario P. Colombo

COMPANION DIAGNOSTICS AND CANCER BIOMARKERS

- 376** **Microdose-Induced Drug–DNA Adducts as Biomarkers of Chemotherapy Resistance in Humans and Mice**
Maïke Zimmermann, Si-Si Wang, Hongyong Zhang, Tzu-yin Lin, Michael Malfatti, Kurt Haack, Ted Ognibene, Hongyuan Yang, Susan Airhart, Kenneth W. Turteltaub, George D. Cimino, Clifford G. Tepper, Alexandra Drakaki, Karim Chamie, Ralph de Vere White, Chong-xian Pan, and Paul T. Henderson

- 388** **HEXIM1 as a Robust Pharmacodynamic Marker for Monitoring Target Engagement of BET Family Bromodomain Inhibitors in Tumors and Surrogate Tissues**
Xiaoyu Lin, Xiaoli Huang, Tamar Uziel, Paul Hessler, Daniel H. Albert, Lisa A. Roberts-Rapp, Keith F. McDaniel, Warren M. Kati, and Yu Shen

MODELS AND TECHNOLOGIES

- 397** **Repositioning FDA-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon Cancer Epigenome**
Noël J.-M. Raynal, Elodie M. Da Costa, Justin T. Lee, Vazganush Gharibyan, Saira Ahmed, Hanghang Zhang, Takahiro Sato, Gabriel G. Malouf, and Jean-Pierre J. Issa
- 408** **Near Infrared Photoimmunotherapy in a Transgenic Mouse Model of Spontaneous Epidermal Growth Factor Receptor (EGFR)-expressing Lung Cancer**
Yuko Nakamura, Zoe Weaver Ohler, Deborah Householder, Tadanobu Nagaya, Kazuhide Sato, Shuhei Okuyama, Fusa Ogata, Dagane Daar, Tieu Hoa, Peter L. Choyke, and Hisataka Kobayashi



AC icon indicates Author Choice


For more information please visit www.aacrjournals.org



Table of Contents

ABOUT THE COVER

The cover shows a crystal structure of EGFR protein with afatinib, 2nd generation EGFR-tyrosine kinase inhibitor. Amino acid residues of the novel L792F and C797S, in addition to the conventional T790M, mutations as the mechanisms of acquired resistance against afatinib are colored. For details, see the article by Kobayashi and colleagues on page 357 of this issue.



Molecular Cancer Therapeutics

16 (2)

Mol Cancer Ther 2017;16:261-414.

Updated version Access the most recent version of this article at:
<http://mct.aacrjournals.org/content/16/2>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://mct.aacrjournals.org/content/16/2>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.